The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01702896
: October 10, 2012
Last Update Posted
: June 3, 2015
Western Regional Medical Center
Information provided by (Responsible Party):
Walter Quan Jr., MD, Western Regional Medical Center
The purpose of this study is to determine whether Interleukin-2 at the dose and schedule used in this study will help to increase tumor shrinkage
Condition or disease
In this phase II trial, the previously described IL-2 schedule (daily IL-2 for 5 days (per week) every 3 weeks) will be tested in a larger cohort of patients with melanoma to attempt to determine the response rate, median duration of response, and median survival. The dose intensity of this schedule would allow a patient treated on this regimen to achieve the target threshold (> 1440 million IU/m2/year).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have a histologic diagnosis of metastatic melanoma. Patients may have received prior systemic therapy or may be previously untreated.
Patients must have bi-dimensional measurable disease on physical exam or radiologic studies.
ECOG performance status of 0 or 1 and estimated survival of at least 3 months.
White blood count of > 3500/mm3, platelet count > 100,000/mm3, hemoglobin > 9.0 gm/dl; bilirubin, ALT, AST < 3 x upper limit of normal; serum creatinine < 2.0 mg/dl.
Patients must undergo a low-level cardiac stress test as a screen for possible atherosclerotic heart disease. Patients with a positive stress test would be excluded from this trial.
Patients with elevated temperatures > 100.5 F must have sources of occult infection excluded.
Patients must be felt to have recovered from effects of prior therapy, such as > 2 weeks after prior chemotherapy.
Patient consent must be obtained prior to entrance onto study.
Women of childbearing potential must have a negative pregnancy test and must take adequate precautions to prevent pregnancy during treatment
Medical illness requiring corticosteroids or other immunosuppressive agents (such as cyclosporin or methotrexate.
Autoimmune disease such as inflammatory arthritis which could be exacerbated by immune-based therapy.
Prior history of psychiatric disorder which could be exacerbated by interleukin-2.
Lactation or pregnancy.
Evidence of significant cardiovascular disease including history of recent (< 6 months prior) myocardial infarction, congestive heart failure, primary cardiac arrhythmias (not due to electrolyte disorder or drug toxicity, for example) beyond occasional PVC's, angina, positive low-level stress test, or cerebrovascular accident.